Y A W N. As We Said Before -- Halozyme's Claim Is Largely Obviated -- By An Alteogen License US Merck Bought And Paid For [Power-Alley Stuff].

As we said in March 2025, this isn't going to be any big deal for US Merck.

And the ruling seems. . . a little "home-court" protective, of Halozyme. [Note all the trademark naming rights spats still dotting the globe -- between US Merck and German Merck (no relation).]

So it seems a German patent court has issued an injunction, in Germany only, for formulations of pembrolizumab that "read on" Halozyme tech. What MSM stories fail to mention was that Merck has already licensed an Alteogen-invented, separate human hyaluronidase variant, one not mentioned in any of the Halozyme patents, either as a claim, or as known prior art.

So this is very likely to amount to almost no damages, payable to Halozyme. Here's the rather breathless MSM version, though -- and a bit:

. . .A court in Munich has granted a preliminary injunction to Halozyme that prevents Merck from distributing the subcutaneous version of its cancer treatment Keytruda (pembrolizumab) in Germany.

Halozyme previously filed a patent infringement lawsuit against Merck arguing that the SC version violates patents related to its MDASE drug delivery system. . . .

Y A W N. Now you know. And the hearing in Nashville has been scrubbed. Probably January 2026, now. Onward, grinning -- I will head there, straight from. . . the cacti -- of Verado, Arizona.

नमस्ते